# US 2014/0271527 A1 · Subcutaneous delivery of polymer conjugates of therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271527 A1
- Document ID: US20140271527A1
- Status: Published application
- Kind: A1
- Application number: 14/355,515
- Filed: 2012-11-01
- Published: 2014-09-18
- Earliest claimed: 2011-11-01
- Assignees: Serina Therapeutics, Inc.
- Applicants: Serina Therapeuitcs, Inc.
- Inventors: Randall Moreadith; Kunsang Yoon; Zhihao Fang; Rebecca Weimer; Bekir Dizman; Tacey Viegas; Michael David Bentley
- Web page: https://patentgrep.com/patent/US20140271527A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/381: having five-membered rings
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.

## Claims

### Claim 1

A polymer conjugate, the polymer conjugate comprising a water soluble polymer and an agent, the agent linked to the water soluble polymer by a releasable linker, the releasable linker cleavable in a subject and providing a sustained, controllable delivery of the agent over a period of days to weeks.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The polymer conjugate of claim 1, wherein the agent is useful for the treatment of Parkinson's Disease, a disorder characterized by dopamine insufficiency, a disorder characterized by excessive GABA re-uptake or GABA re-uptake, an anxiety disorder, social anxiety disorder, panic disorder, neuropathic pain, chronic pain, muscle tremors, muscle spasms, seizures, convulsions or epilepsy.

### Claim 4 (depends on 1)

The polymer conjugate of claim 1, wherein the agent is a dopamine agonist, an adenosine A2A antagonist, an anticholinergic, a monamine oxidase-B inhibitor, a catechol-O-methyl transferase (COMT) inhibitor or a GABA up-take inhibitor.

### Claim 5 (depends on 1)

The polymer conjugate of claim 1, wherein the agent is rotigotine, (−)rotigotine, pramipexole, quinagolide, fenoldopam, apomorphine, 5-OH-DPAT, ropinirole, pergolide, cabergoline, bromocriptine.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The polymer conjugate of claim 1, wherein the agent is trihexyphenidyl, piperidin, hyoscyamine, seligiline, rasgaline, tolcapone, entacapone, caffeine, theophylline, istradefylline or preladenant.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The polymer conjugate of claim 1, wherein the agent is tiagabine or nipecotic acid.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The polymer conjugate of claim 1, wherein the poly(oxazoline) polymer has a molecular weight range of 300 Da to 200,000 Da.

### Claim 13 (depends on 1)

The polymer conjugate of claim 1, wherein the poly(oxazoline) polymer has the formula
wherein
R is an initiating group;
L is a releasable linker containing a cleavable moiety cleavable in a subject and providing a sustained, controllable delivery of the dopamine agonist over a period of days to weeks;
A is an agent;
POZ is a poly(oxazoline) polymer;
n is from 1-1000;
b is from 1-50, provided that b is not greater than n; and
T is a terminating group.

### Claim 14 (depends on 13)

The polymer conjugate of claim 13, wherein T is Z-B-Q
wherein
Z is S, O, or N;
B is an optional linking group; and
Q is a terminal portion of a terminating nucleophile.

### Claim 15 (depends on 13)

The polymer conjugate of claim 13, wherein R is hydrogen, alkyl or substituted alkyl.

### Claim 16 (depends on 13)

The polymer conjugate of claim 13, wherein the cleavable moiety contains at least one ester, carboxylate ester, carbonate ester, carbamate, disulfide, acetal, hemiacetal, phosphate, phosphonate or amide group.

### Claim 17 (depends on 13)

The polymer conjugate of claim 13, wherein L has the structure
wherein
R3 is a linker linking the triazole moiety to the polymer chain;
R4 is -R6-R7-R8-;
R6 is a substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl
R7 is a group containing at least a portion of the cleavable moiety;
R8 is absent or is O, S, CRc, or NRc; and
Rc is H or substituted or unsubstituted alkyl.

### Claim 18 (depends on 17)

The polymer conjugate of claim 17, wherein R7 is —Ra—(O)—Rb—, —Ra—O—C(O)—Rb—, —Ra—C(O)—NH—(C6H4)—O—C(O)—Rb—, —Ra—C(O)—Rb—, —Ra—C(O)—O—Rb—, —Ra—O—CH(OH)—Rb—, Ra—S—S—Rb—, Ra—O—P(O)(OR11)—Rb—, or —Ra—C(O)—Rb—, wherein Ra and Rb are each independently absent or substituted or unsubstituted alkyl and R11 is H or a substituted or unsubstituted C1-C5 alkyl.

### Claim 19 (depends on 17)

The polymer conjugate of claim 17, wherein R7 is —Ra—C(O)—O—Rb— and Ra, Rb and R8 are each absent, R7 is —Ra—C(O)—Rb—, —Ra—O—C(O)—Rb—, —Ra—CH(OH)—Rb— or Ra—O—P(O)(OR11)—Rb—, Ra and Rb are each absent and R8 is O, R7 is —Ra—O—C(O)—Rb— or —Ra—C(O)—Rb, Ra and Rb are each absent and R8 is NH, or R7 is Ra—S—S—Rb—, Ra and Rb are each absent and R8 is absent.

### Claim 20 (depends on 17)

The polymer conjugate of claim 17, wherein R3 is —C(O)—(CH2)3 and R4 is —CH2—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2(CH3)—C(O)—O— or —CH2CH2CH2—C(O)—O.

### Claim 21 (depends on 17)

The polymer conjugate of claim 17, wherein R3 is —C(O)—(CH2)3 and R4 is —CH2—CH2—O—C(O), —CH2—CH2—CH2—O—C(O), —CH2—CH2—CO—NH—(C6H4)—O—C(O)— or —(CH2CH2O)d—C(O)—, where d is 1-10.

### Claim 22 (depends on 13)

The polymer conjugate of claim 13 having the structure
wherein
R is an initiating group;
L is a releasable linker containing a cleavable moiety cleavable in a subject and providing a sustained, controllable delivery of the dopamine agonist over a period of days to weeks;
A is an agent;
a is ran which indicates a random copolymer or block which indicates a block copolymer;
o is from 1-50;
m is from 1-1000; and
T is a terminating group.

### Claim 23 (depends on 22)

The polymer conjugate of claim 22, wherein T is Z-B-Q
wherein
Z is S, O, or N;
B is an optional linking group; and
Q is a terminal portion of a terminating nucleophile.

### Claim 24 (depends on 22)

The polymer conjugate of claim 22, wherein R is hydrogen, alkyl or substituted alkyl.

### Claim 25 (depends on 22)

The polymer conjugate of claim 22, wherein the releasable linker contains at least one ester, carboxylate ester, carbonate, ester, carbamate, disulfide, acetal, hemiacetal, phosphate, phosphonate or amide group.

### Claim 26 (depends on 22)

The polymer conjugate of claim 22, wherein L has the structure
wherein
R3 is a linker linking the triazole moiety to the polymer chain;
R4 is -R6-R7-R8-;
R6 is a substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl
R7 is a group containing at least a portion of the cleavable moiety;
R8 is absent or is O, S, CRc, or NRc; and
Rc is H or substituted or unsubstituted alkyl.

### Claim 27 (depends on 26)

The polymer conjugate of claim 26, wherein R7 is —Ra—(O)—Rb—, —Ra—O—C(O)—Rb—, —Ra—C(O)—NH—(C6H4)—O—C(O)—Rb—, —Ra—C(O)—Rb—, —Ra—C(O)—O—Rb—, —Ra—CH(OH)—Rb—, Ra—S—S—Rb—, Ra—O—P(O)(OR11)—Rb—, or —Ra—C(O)—Rb—, wherein Ra and Rb are each independently absent or substituted or unsubstituted alkyl and R11 is H or a substituted or unsubstituted C1-C5 alkyl.

### Claim 28 (depends on 26)

The polymer conjugate of claim 26, wherein R7 is —Ra—C(O)—O—Rb— and Ra, Rb and R8 are each absent, R7 is —Ra—C(O)—Rb—, —Ra—O—C(O)—Rb—, —Ra—CH(OH)—Rb— or Ra—O—P(O)(OR11)—Rb—, Ra and Rb are each absent and R8 is O, R7 is —Ra—O—C(O)—Rb— or —Ra—C(O)—Rb, Ra and Rb are each absent and R8 is NH, or R7 is Ra—S—S—Rb—, Ra and Rb are each absent and R8 is absent.

### Claim 29 (depends on 26)

The polymer conjugate of claim 26, wherein R3 is —C(O)—(CH2)3 and R4 is —CH2—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2(CH3)—C(O)—O— or —CH2CH2CH2—C(O)—O.

### Claim 30 (depends on 26)

The polymer conjugate of claim 26, wherein R3 is —C(O)—(CH2)3 and R4 is —CH2—CH2—O—C(O), —CH2—CH2—CH2—O—C(O), —CH2—CH2—CO—NH—(C6H4)—O—C(O)— or —(CH2CH2O)d—C(O)—, where d is 1-10.

### Claim 31 (depends on 23)

The polymer conjugate of claim 23, wherein the polymer conjugate has structure:
wherein p is an integer from 1 to 18.

### Claim 32

(canceled)

### Claim 33 (depends on 23)

The polymer conjugate of claim 23, wherein the polymer
conjugate has structure:
wherein p is an integer from 1 to 18.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The polymer conjugate of claim 1, wherein water-soluble polymer is poly(oxazoline), poly(5,6-dihydro-4h-1,3-oxazine), poly(ethylene glycol), dextran, dextran modified by oxidation, poly(glycerol), poly(glutamate), poly(hydroxypropylmethacrylate), poly(glycosaminoglycan), poly(sialic acid), poly(acryloyloxyethylphosphorylcholine) and copolymers of the foregoing.

### Claim 46 (depends on 1)

The polymer conjugate of claim 1, wherein the water-soluble polymer is poly(oxazoline), poly(ethylene glycol), dextran or dextran modified by oxidation.

### Claim 47 (depends on 1)

The polymer conjugate of claim 1, wherein the water-soluble polymer is poly(oxazoline).

### Claim 48 (depends on 1)

The polymer conjugate of claim 1, wherein the poly(oxazoline) contains a pendant group and the agent is linked to the poly(oxazoline) via the pendant group.

### Claim 49 (depends on 1)

The polymer conjugate of claim 1 wherein the poly(oxazoline) contains from 2 to 50 pendant groups and the agent is linked to the poly(oxazoline) via at least a portion of the pendant groups.

### Claim 50 (depends on 1)

The polymer conjugate of claim 1, wherein the water-soluble polymer is poly(ethylene glycol).

### Claim 51 (depends on 50)

The polymer conjugate of claim 50, wherein the poly(ethylene glycol) is linear, multi-arm, branched, forked, pendent, or dendritic.

### Claim 52 (depends on 1)

The polymer conjugate of claim 1, wherein the water-soluble polymer is dextran or dextran modified by oxidation.

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55 (depends on 1)

A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system or a disease or condition characterized by excessive GABA re-uptake or GABA re-uptake, the method comprising the step of administering to the subject an amount of a polymer conjugate of claim 1.

### Claim 56 (depends on 55)

The method of claim 55, wherein the disease or condition is Parkinson's disease or restless leg syndrome.

### Claim 57

(canceled)

### Claim 58 (depends on 55)

The method of claim 55, wherein the agent is a dopamine agonist, an adenosine A2A antagonist, an anticholinergic, a monamine oxidase-B inhibitor or a catechol-O-methyl transferase (COMT) inhibitor.

### Claim 59 (depends on 55)

The method of claim 55, wherein the agent is rotigotine, (−)rotigotine, pramipexole, quinagolide, fenoldopam, apomorphine, 5-OH-DPAT, ropinirole, pergolide, cabergoline, or bromocriptine.

### Claim 60 (depends on 55)

The method of claim 55, wherein the agent is trihexyphenidyl, piperidin, hyoscyamine, seligiline, rasgaline, tolcapone, entacapone, caffeine, theophylline, istradefylline or preladenant

### Claim 61 (depends on 55)

The method of claim 55, wherein the water soluble polymer is poly(oxazoline), poly(5,6-dihydro-4h-1,3-oxazine), dextran, dextran modified by oxidation, polyethylene glycol (PEG), poly(hydroxypropylmethacrylate), polyglutamic acid, polylactic-polyglutamic acid mixture, polysialic acid, polycaprolactone, polyvinylpyrrolidone, poly(sialic acid), polyglycosaminoglycan, polyglycerol, poly(acryloyloxyethylphosphorylcholine), and methacrylate-based copolymer with synthetic forms of phosphorylcholine and copolymers of the foregoing.

### Claim 62 (depends on 55)

The method of claim 55, wherein the water soluble polymer is poly(oxazoline), polyethylene glycol), dextran or oxidized dextran.

### Claim 63 (depends on 55)

The method of claim 55, wherein the polymer conjugate is administered by subcutaneous administration.

### Claim 64 (depends on 55)

The method of claim 55, wherein release of the agent is controlled by the nature of the linking group, the nature of the polymer, the nature of the agent, the size of the polymer, the method of delivery or a combination of the foregoing.

### Claim 65 (depends on 13, 22, 31, 33, 55)

The method of claim 55, wherein the polymer conjugate is a conjugate of any one of claims 13, 22, 31 and 33.

### Claim 66

(canceled)

### Claim 67 (depends on 55)

The method of claim 55, wherein the disease or condition is an anxiety disorder, social anxiety disorder, panic disorder, neuropathic pain, chronic pain, muscle tremors, muscle spasms, seizures, convulsions or epilepsy.

### Claim 68 (depends on 55)

The method of claim 55, wherein the agent is tiagabine or nipecotic acid.

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)
